Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Psychotherapy for PTSD in Dutch Military Veterans
2025-521488-11-00Phase 2Authorised
- Sponsor
- ARQ National Psychotrauma Centre
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by ARQ National Psychotrauma Centre. Primary endpoints: Feasibility: screen failures and dropout, Treatment acceptability and adherence and 6 more. Planned start Jun 2026; status: authorised.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2025-521488-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521488-11-00.